Metformin as a Repurposed Longevity Drug
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The observational mortality signal in diabetic metformin users and the FDA's agreement to the TAME trial design reflect a credible research hypothesis, but the definitive randomized trial testing metformin against aging-related outcomes in non-diabetics (TAME) remains incomplete, and animal lifespan data are mixed, so the human-longevity claim is preliminary.
Reference only. Not medical advice.
Metformin is a first-line, decades-old oral diabetes medication that lowers blood glucose primarily by reducing hepatic glucose production and improving insulin sensitivity, through mechanisms including AMPK activation and mitochondrial complex I inhibition. Because these pathways overlap with those implicated in aging biology (energy sensing, inflammation, and mitochondrial function), and because some observational studies found diabetic patients taking metformin had lower mortality than matched non-diabetic populations, metformin became a leading candidate for repurposing as a general longevity drug. This observational signal is confounded by factors including "healthy user" bias, differences in disease severity, and how comparison groups are selected, and metformin's benefit in animal lifespan studies is mixed and dose-dependent, with some mouse studies from the NIA Interventions Testing Program showing modest lifespan extension only at low doses and none or even mild harm at higher doses. The TAME trial, a proposed roughly 3,000-person, multi-site, placebo-controlled randomized trial in adults aged 65 to 79 without diabetes but at elevated risk of age-related disease, was designed with FDA input specifically to test whether metformin can delay a composite of cardiovascular disease, cancer, dementia, or death, and its regulatory significance is that the FDA agreed in principle to accept a composite aging-related endpoint, opening a template pathway other researchers could use. As of the mid-2020s, TAME has faced ongoing funding challenges and has not been completed or fully reported, so the central question, whether metformin slows biological aging or extends lifespan in non-diabetic humans, remains formally unanswered. Metformin's safety profile is well established from over 60 years of diabetes use: it is generally well tolerated, with gastrointestinal side effects being most common, and rare but serious risk of lactic acidosis primarily in people with significant kidney impairment. Current status is that metformin is FDA-approved only for type 2 diabetes (and some off-label uses like PCOS and prediabetes), and its use for longevity in people without diabetes is off-label and not supported by completed randomized outcome trials, though it is among the more plausible repurposed longevity candidates given its long safety record.
Metformin is a first-line, decades-old oral diabetes medication that lowers blood glucose primarily by reducing hepatic glucose production and improving insulin sensitivity.
Safety in detail
Metformin has a long safety record in diabetes care but carries a rare risk of lactic acidosis in people with significant renal impairment, and common gastrointestinal side effects; it should not be started for longevity purposes without medical supervision.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Metformin descends from galegine, a compound in Galega officinalis (French lilac or goat's rue), a plant used in European folk medicine for centuries to treat symptoms resembling diabetes. Metformin itself was first synthesized and described chemically in 1922 by Emil Werner and James Bell, but it was not developed as a diabetes treatment until French physician Jean Sterne published the first human trials in 1957. It became a first-line type 2 diabetes therapy globally after the UK Prospective Diabetes Study (UKPDS) reported in 1998 that metformin reduced diabetes-related complications and mortality compared with conventional therapy. Interest in metformin as a general longevity drug grew from the 2010s onward after observational studies suggested diabetic patients on metformin sometimes had better survival than non-diabetic controls, leading the American Federation for Aging Research to design the TAME (Targeting Aging with Metformin) trial with FDA input as a template for testing drugs against aging itself rather than a single disease.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Metformin as a Repurposed Longevity Drug. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.